21 November 2025
November BNF + BNFC Content Updates
British National Formulary
This update contains 32 significant changes, 3 dose changes, 3 new monographs, 1 new preparation, and 1 deleted preparation.
Significant changes
Antibacterials, use for prophylaxis: updated guidance for Haemophilus influenzae type b infection: prevention of secondary disease.
Azithromycin: new indication and dose for prevention of secondary case of Haemophilus influenzae type b disease.
Bee venom extract: name change to bee venom extracts.
Ciprofloxacin: new indication and dose for prevention of secondary case of Haemophilus influenzae type b disease.
COVID-19 vaccine: monograph updated to reflect current guidance.
COVID-19 vaccines: updated guidance for immunisation.
Diphtheria vaccine: updated guidance for immunisation.
Factor VIIa (recombinant): name change to factor VIIa.
Factor XIII A-subunit (recombinant): name change to factor XIII A-subunit.
Fibrinogen, dried: name change to fibrinogen.
Grass pollen extract: name change to grass pollen extracts.
Guselkumab: new indications and doses for Crohn’s disease and ulcerative colitis.
Haemophilus influenzae type b conjugate vaccine: updated guidance for immunisation.
Heparin (unfractionated): name change to heparin.
Hepatitis B vaccine: updated guidance for immunisation.
House dust mite extract: name change to house-dust mite extracts.
Hydroxyethylcellulose: name change to hyetellose.
Immunisation schedule: updated guidance.
Liraglutide: monograph updated to incorporate new preparations.
Measles, Mumps and Rubella vaccine: updated guidance for immunisation.
Meningococcal vaccines: updated guidance for immunisation.
Paracetamol: reminder that taking paracetamol during pregnancy remains safe [MHRA/CHM advice].
Paraffin, yellow, soft: name change to yellow soft paraffin.
Pertussis vaccine: updated guidance for immunisation.
Pneumococcal vaccine: updated guidance for immunisation.
Poliomyelitis vaccine: updated guidance for immunisation.
Protein C concentrate: name change to protein C.
Silver sulfadiazine: name change to sulfadiazine silver.
Tetanus vaccine: updated guidance for immunisation.
Tree pollen extract: name change to tree pollen extracts.
Vaccination, general principles: updated guidance for vaccines and asplenia, splenic dysfunction, or complement disorders.
Wasp venom extract: name change to wasp venom extracts.
Dose changes
Ergometrine maleate [update to dosing for postpartum haemorrhage caused by uterine atony].
Ergometrine with oxytocin [update to dosing for postpartum haemorrhage caused by uterine atony].
Paclitaxel (albumin-bound) [update to indications and dose for non-small cell lung cancer in adults].
New monographs
Elahere® [mirvetuximab soravtansine] for Ovarian cancer, Fallopian tube cancer, Peritoneal cancer.
Tzield® [teplizumab] for Type 1 diabetes mellitus [to delay onset of stage 3 in those with stage 2 disease].
Vimkunya® [chikungunya vaccine (inactivated)] for Immunisation against chikungunya.
New preparations
Paclitaxel albumin-bound for Ovarian cancer [conventional paclitaxel only], Non-small cell lung cancer [conventional paclitaxel and albumin-bound paclitaxel], AIDS-related Kaposi’s sarcoma [conventional paclitaxel only], Breast cancer [conventional paclitaxel and albumin-bound paclitaxel], Pancreatic adenocarcinoma [albumin-bound paclitaxel only].
Deleted preparations
Victoza® [liraglutide]
BNF for Children
This update contains 31 significant changes, 2 new monographs, and 1 deleted monograph.
Significant changes
Antibacterials, use for prophylaxis: updated guidance for Haemophilus influenzae type b infection: prevention of secondary disease.
Azithromycin: new indication and dose for prevention of secondary cases of Haemophilus influenzae type b disease.
Bee venom extract: name change to bee venom extracts.
Ciprofloxacin: new indication and dose for prevention of secondary cases of Haemophilus influenzae type b disease.
COVID-19 vaccine: monograph updated to reflect current guidance.
COVID-19 vaccines: updated guidance for immunisation.
Diphtheria vaccine: updated guidance for immunisation.
Factor VIIa (recombinant): name change to factor VIIa.
Factor XIII A-subunit (recombinant): name change to factor XIII A-subunit.
Fibrinogen, dried: name change to fibrinogen.
Grass pollen extract: name change to grass pollen extracts.
Haemophilus influenzae type b conjugate vaccine: updated guidance for immunisation.
Heparin (unfractionated): name change to heparin.
Hepatitis B vaccine: updated guidance for immunisation.
House dust mite extract: name change to house-dust mite extracts.
Hydroxyethylcellulose: name change to hyetellose.
Immunisation schedule: updated guidance.
Liraglutide: monograph updated to incorporate new preparations.
Measles, Mumps and Rubella vaccine: updated guidance for immunisation.
Meningococcal vaccines: updated guidance for immunisation.
Paracetamol: reminder that taking paracetamol during pregnancy remains safe [MHRA/CHM advice].
Paraffin, yellow, soft: name change to yellow soft paraffin.
Pertussis vaccine: updated guidance for immunisation.
Pneumococcal vaccine: updated guidance for immunisation.
Poliomyelitis vaccine: updated guidance for immunisation.
Protein C concentrate: name change to protein C.
Silver sulfadiazine: name change to sulfadiazine silver.
Tetanus vaccine: updated guidance for immunisation.
Tree pollen extract: name change to tree pollen extracts.
Vaccination, general principles: updated guidance for vaccines and asplenia, splenic dysfunction, or complement disorders.
Wasp venom extract: name change to wasp venom extracts.
New monographs
Tzield® [teplizumab] for Type 1 diabetes mellitus [to delay onset of stage 3 in those with stage 2 disease.
Vimkunya® [chikungunya vaccine (inactivated)] for Immunisation against chikungunya.
Deleted preparations
Victoza® [liraglutide]
